# Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult

> **NCT02553837** · PHASE3 · UNKNOWN · sponsor: **Green Cross Corporation** · enrollment: 317 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Hantavax injection

## Key facts

- **NCT ID:** NCT02553837
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2017-08
- **Final completion:** 2022-07
- **Target enrollment:** 317 (ESTIMATED)
- **Last updated:** 2016-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02553837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02553837, "Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02553837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*